Novo Nordisk Sharpens Its Pipeline Edge as Longevity Pivot Takes Shape

The Danish pharmaceutical heavyweight arrived at the American Diabetes Association congress in New Orleans armed with a double dose of clinical ammunition. Beyond the widely watched CagriSema data, the company unveiled Phase 2 results for a lesser-known candidate that could reshape its pipeline narrative. The experimental drug Zenagamtide delivered a striking HbA1c reduction of 1.71 percentage points in patients with Type 2 diabetes over 36 weeks at the highest 40 mg dose, with nearly 89% of that group hitting the clinically meaningful threshold of below 7%. Body weight tumbled 14.6%. Novo Nordisk expects to launch Phase 3 in the second half of 2026, with initial readouts unlikely before 2028.

The company’s more advanced combination therapy, CagriSema — an amylin analogue paired with a GLP-1 receptor agonist — also hit its marks across the REIMAGINE-1-to-3 programme. In REIMAGINE-1, the 2.4 mg/2.4 mg dose produced a 2.33 percentage point drop in HbA1c and a 12.0% weight loss versus placebo. The results were simultaneously published in The Lancet and The Lancet Diabetes & Endocrinology. Yet CagriSema faces an unresolved competitive shadow. In the head-to-head REDEFINE-4 study against Eli Lilly’s tirzepatide, it delivered a 23% weight reduction after 84 weeks but failed to meet the non-inferiority primary endpoint. A regulatory decision on the REIMAGINE programme is anticipated in the fourth quarter of 2026.

These clinical milestones underpin a broader strategic pivot. Novo Nordisk is signalling it wants to shed its narrow identity as a diabetes and obesity company and reposition itself around longevity and aesthetics — a shift that comes as the stock has shed roughly 15% since the start of the year. The 40 abstracts on semaglutide’s cardiometabolic effects presented in New Orleans, covering obstructive sleep apnoea, liver health and hypertension, provide the scientific scaffolding for this multi-indication ambition.

Regulatory progress elsewhere added to the week’s positive tone. The UK became the first European market to approve the oral version of Wegovy — a landmark that lifted market sentiment and helped push a recent cybersecurity incident to the background. Novo Nordisk’s shares closed the week at €38.03, good for a 2% weekly advance after a turbulent stretch.

Should investors sell immediately? Or is it worth buying Novo Nordisk?

The company is also leaning on its balance sheet. Since 4 February 2026, it has bought back roughly 18.8 million B-shares at an average price of DKK 264.32, totalling nearly DKK 5 billion. The overall programme authorises up to DKK 15 billion over twelve months — yet the stock has struggled to muster a sustained rally.

Technically, the shares remain 8% below their 200-day moving average of €41.43, a level analysts view as critical for any genuine trend reversal. The relative strength index sits at 53.6, in neutral territory. From the 52-week high of €70.13 struck in June 2025, the stock has lost nearly half its value. The operating outlook remains cautious: after first-quarter results in May, management nudged guidance to a range of minus 4% to minus 12% for both adjusted revenue growth and adjusted operating profit, citing pricing pressure, political risks and patent expirations.

Investors will get the next concrete update on 5 August 2026, when Novo Nordisk reports second-quarter numbers before the market opens. Whether the longevity narrative and the pipeline momentum can shift institutional sentiment remains an open question — one that may hinge on further analyst reaction to the strategic repositioning in the weeks ahead.